ライフサイエンスコーパス: tobacco dependence

1 d adverse effects with pharmacotherapies for tobacco dependence.

2 ophrenia have an exceptionally high risk for tobacco dependence.

3 ble, safe, and effective in the treatment of tobacco dependence.

4 fiant disorders, as well as with alcohol and tobacco dependence.

5 rm of treatment for individual patients with tobacco dependence.

6 ked to motivationally significant aspects of tobacco dependence.

7 y to nicotine may influence vulnerability to tobacco dependence.

8 vironmental and biological codeterminants of tobacco dependence.

9 est for those who were in the top tertile of tobacco dependence (31.3%; 95% CI, 25.0%-37.7%), were no

10 bling were significantly more likely to have tobacco dependence (84.0% versus 61.1%) and antisocial p

11 ctive models to manage chronic diseases like tobacco dependence across transitions in care.

12 de practical guidance for providers to treat tobacco dependence among PWH.

13 duce early onset tobacco smoking and risk of tobacco dependence among smokers.

14 ssation in PWH, and studies of treatment for tobacco dependence among the general population and amon

15 receptors (nAChRs) play an important role in tobacco dependence and a potential therapeutic role in n

16 w class of medications for treatment of both tobacco dependence and cannabis dependence.

17 r proposed approach to a genetic data set on tobacco dependence and found a significant interaction b

18 ype on chromosome 15 underlying the risk for tobacco dependence and lung cancer.

19 tion of new therapeutic targets for treating tobacco dependence and other addictions.

20 CHRNA3 risk alleles can increase the risk of tobacco dependence and smoking-related diseases in human

21 CHRNA3 risk alleles can increase the risk of tobacco dependence and smoking-related diseases in human

22 (nAChR) subunit, increases vulnerability to tobacco dependence and smoking-related diseases, but lit

23 (nAChR) subunit, increases vulnerability to tobacco dependence and smoking-related diseases, but lit

24 Both tobacco dependence and such conditions as diabetes are s

25 d creatine levels correlated negatively with tobacco dependence, and creatine correlated negatively w

26 istration-approved medications used to treat tobacco dependence, bupropion and nicotine replacement t

27 ptor (nAChR) subunit gene, increases risk of tobacco dependence but underlying mechanisms are unclear

28 ptor (nAChR) subunit gene, increases risk of tobacco dependence but underlying mechanisms are unclear

29 king cessation could elucidate the nature of tobacco dependence, enhance risk assessment, and support

30 mplementation of fibrates as a treatment for tobacco dependence, especially in smokers with abnormal

31 Although the efficacy of pharmacotherapy for tobacco dependence has been previously demonstrated, the

32 While subjective aspects of tobacco dependence have been extensively examined as pre

33 duals with mental illness have high rates of tobacco dependence; however, little is known about what

34 ief behavioural support for the treatment of tobacco dependence in patients with tuberculosis.

35 ducation, including a lack of integration of tobacco dependence information throughout all 4 years of

36 quit smoking after discharge and received a tobacco dependence intervention in the hospital; 92% of

37 Tobacco dependence is a chronic, relapsing condition tha

38 Intensive intervention for tobacco dependence is a more effective smoking cessation

39 Tobacco dependence is an addiction with high rates of re

40 Tobacco dependence is difficult to treat, with the vast

41 Treating tobacco dependence is one of the most cost-effective act

42 The findings were specific for tobacco dependence; odds of marijuana dependence were no

43 are likely to increase the effectiveness of tobacco-dependence pharmacotherapy.

44 Tobacco dependence should share the status of other chro

45 ith varenicline, the leading monotherapy for tobacco dependence, smoking abstinence rates remain low.

46 d for associations of metabolite levels with tobacco dependence, smoking history, craving, and withdr

47 gave evidence of three classes pertinent to tobacco dependence syndrome in smokers by young adulthoo

48 ore likely to meet DSM criteria for lifetime tobacco dependence than offspring of mothers who reporte

49 bacco do not receive the key intervention of tobacco dependence treatment (TDT).

50 multistakeholder committee with expertise in tobacco dependence treatment and/or LDCT screening.

51 ividualize the type, dosage, and duration of tobacco dependence treatment based on genotype, and maxi

52 Most PWH who smoke want to quit, but tobacco dependence treatment has not been widely integra

53 ss of triple-combination pharmacotherapy for tobacco dependence treatment in these high-risk smokers

54 A particular challenge in tobacco dependence treatment is the development of effec

55 The optimal duration of tobacco dependence treatment is unknown, and some smoker

56 h established pharmacological and behavioral tobacco dependence treatment therapies as primary goals

57 Combining pharmacotherapies for tobacco-dependence treatment may increase smoking abstin

58 betes are well covered by insurance, whereas tobacco dependence treatments are often limited.

59 nd naltrexone, have yielded mixed results as tobacco dependence treatments.

60 sorders, severe substance use disorders, and tobacco dependence were calculated using the Composite I

61 e management model is effective for treating tobacco dependence, which deserves as high a priority in

62 percentage of smokers receive treatment for tobacco dependence with counseling and/or medication, th

63 vity to which may influence vulnerability to tobacco dependence, yet mechanisms of nicotine avoidance